ArticleClinical and experimental hepatology2025
Three-year outcomes under pemafibrate therapy in patients with metabolic dysfunction-associated steatotic liver disease: a long-term observational study.
Satoshi Shinozaki et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.